Belite Bio, Inc American Depositary Shares (BLTE) Stock Price
BLTEStock
$151.72+135.19%52W
Market Cap$6.11B
P/E—
PEG Ratio—
Div yield—
Beta-1.22
BLTE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-30.43%
Price vs S&P 500 (4W)-3.52%
VGM Score57.97
BLTE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.78 | -$0.70 | +9.93%(+$0.08) | |
| Q1 2026 | -$0.64 | -$0.68 | -5.78%(-$0.04) | |
| Q4 2025 | -$0.54 | -$0.70 | -30.32%(-$0.16) | |
| Q3 2025 | -$0.49 | -$0.65 | -32.65%(-$0.16) | |
| Q2 2025 | -$0.42 | -$0.50 | -19.76%(-$0.08) |
BLTE Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BLTEBelite Bio, Inc American Depositary Shares | — | — | C | $151.72 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Belite Bio, Inc American Depositary Shares
Belite Bio is a clinical-stage biopharmaceutical company developing novel therapeutics for retinal degeneration and metabolic diseases. Its pipeline includes treatments for age-related macular degeneration, Stargardt disease, nonalcoholic fatty liver disease, type 2 diabetes, and gout.